Serial #79248825
LIVE

Serial Number

79248825

Owner

Jiangsu Ascentage Pharma Inc.

Attorney

Kathryn E. Smith

Filing Date

Aug 10, 2018

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79248825 Trademark

Serial Number: 79248825 • Registration: 5905800

Serial #79248825 is a trademark filed by Jiangsu Ascentage Pharma Inc. on August 10, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Jiangsu Ascentage Pharma Inc. (6 trademarks)

101 Room Of First Floor, Qb3 Buiding,

Entity Type: 99

ASCENTAGE PHARMA (SUZHOU) CO., LTD. (23 trademarks)

68 XINQING ROAD
SUZHOU 215000 , CN

Entity Type: 03

JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC.

Room 101, F/1, Phase 1,

Entity Type: 03

Trademark Details

Filing Date

August 10, 2018

Registration Date

November 12, 2019

Published for Opposition

August 27, 2019

Goods & Services

Medicines for human purposes, namely, medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, next-generation kinase inhibitors and senolytic drugs; prescription drugs for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; medicines for dental purposes; chemical preparations for pharmaceutical or medical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antibiotics; pharmaceutical preparations in the form of injectionable pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the form of tablet for the treatment of cancer, tumors, blood-related diseases, infectious diseases, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; active pharmaceutical ingredients in the nature of drug delivery agents in the form of powders, liquids, and capsules that provide controlled release of active ingredients for a wide variety of pharmaceuticals; active pharmaceutical ingredients in the nature of drug delivery agents in the form of tablets, lozenges, chews, gels, fast dispersing dosage forms, films, ovules, sprays, buccal/mucoadhesive patches for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biochemical medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antiseptics; collyrium; suppositories; medicinal oils; transdermal patches for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; candy, medicated; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic substances in the nature of foods and beverages adapted for medical use; mineral food supplements; nutritional supplements

Filing History

TEAS SECTION 71 RECEIVED
Apr 28, 2026 ES71
NEW REPRESENTATIVE AT IB RECEIVED
Apr 23, 2026 NREP
CHANGE OF OWNER RECEIVED FROM IB
Nov 7, 2025 CHLD
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 21, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Aug 21, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 21, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 21, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 21, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 21, 2025 COAR
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 12, 2024 REM3
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Apr 1, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 1, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 1, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 1, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 1, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 1, 2024 COAR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 27, 2023 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Dec 25, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
May 8, 2020 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Mar 7, 2020 XXSS
GENERIC MADRID TRANSACTION CREATED
Mar 6, 2020 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 12, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 12, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 27, 2019 NPUB
PUBLISHED FOR OPPOSITION
Aug 27, 2019 PUBO
NOTIFICATION PROCESSED BY IB
Aug 23, 2019 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 7, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 7, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 7, 2019 NONP
ASSIGNED TO LIE
Jul 22, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 16, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 16, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 16, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 16, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 16, 2019 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 14, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 13, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 13, 2019 TROA
REFUSAL PROCESSED BY IB
Feb 16, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 26, 2019 RFCS
REFUSAL PROCESSED BY MPU
Jan 26, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 16, 2019 RFCR
NON-FINAL ACTION WRITTEN
Jan 15, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Jan 15, 2019 MAFR
ASSIGNED TO EXAMINER
Jan 11, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 11, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 3, 2019 REPR